Celgene Header body {background: #000; font-family: Arial, Helvetica, sans-serif; font-size: 12px; color: #FFF; text-align: left; margin-top: 50px;}#wrapper-celgene {border: 1px solid #9c9c9c; width: 965px; padding-bottom: 20px; overflow: hidden; background-image: url(http://imaging.ubmmedica.com/all/editorial/cancernetwork/infocenter/celgene/background-celgene.png); background-repeat:repeat-y;}#cn {font-size: 12px; font-weight: bold; margin-bottom: 10px;}#header {margin-left: 25px;}#footer {font-size: 10px; margin-top: 10px;}#wrapper-content {margin: 5px 0 10px 25px;}#panel-left {width: 635px; float: left;}#panel-right {float: left; margin-left: 25px;}#slide {background-image: url(http://imaging.ubmmedica.com/all/editorial/cancernetwork/infocenter/celgene/slide-off.png);width: 265px;height: 91px;margin-bottom: 7px;}#slide .left{width:90px; height: 90px; float: left; border: 1px solid #9c9c9c;}#slide .right{margin: 15px 0 0; float: right; width: 165px;}#slide-hot {background-image: url(http://imaging.ubmmedica.com/all/editorial/cancernetwork/infocenter/celgene/slide-on.png);width: 265px;height: 91px;margin-bottom: 7px;}#slide-hot .left{width:90px; height: 90px; float: left; border: 1px solid #9c9c9c;}#slide-hot .right{margin: 15px 0 0; float: right; width: 165px;}a {color: #fff;}
«
Return to CancerNetwork
Newsletter Stay up to date on recent advances in the multidisciplinary approach to cancer.
Subscribe
September 21st, 2026 Peter Forsyth, MD, discusses a first-in-human trial of intrathecal dendritic cell therapy for leptomeningeal disease from breast cancer.
September 21st, 2026 Adding radiotherapy to tislelizumab and chemotherapy also appeared to prolong progression-free survival in a real-world setting.
September 21st, 2026 “[E]ven if patients relapse following an allogeneic transplant, donor lymphocyte infusions can be incredibly helpful,” said Mary Jo Lechowicz, MD.
September 21st, 2026 The Community Oncology Alliance is urging CMS and Congress to address Medicare Part B drug negotiation policies that threaten independent cancer practices and patient access.
September 21st, 2026 In a phase 1 trial, the MVA-vectored neoantigen vaccine TG4050 produced no dose-limiting toxicities or relapses in those with resected HPV-negative HNSCC.
September 21st, 2026 At SOHO 2026, experts highlighted new findings and advances across diseases including lymphoma, myelodysplastic syndrome, and leukemia.
September 20th, 2026 Poster sessions at WCLC 2026 detail how surgery, nursing, and pathology can contribute to the multidisciplinary care of patients with lung cancer.
September 19th, 2026 A positive CHMP opinion supports the perioperative use of pembrolizumab plus enfortumab vedotin in resectable MIBC regardless of cisplatin eligibility.